Abstract
ABSTRACT − Repeated oral administration of loxoprofen can induce many side effects such as gastric disturbances andacidosis. Therefore, we considered alternative routes of administration for loxoprofen to avoid such adverse effects. The aimof this study was to develop an ethylene-vinyl acetate (EVA) matrix system containing a permeation enhancer for enhancedtransdermal delivery of loxoprofen. The EVA matrix containing loxoprofen was fabricated and the effects of drug con-centration, temperature, enhancer and plasticizer on drug release were studied from the loxoprofen-EVA matrix. The sol-ubility of loxoprofen was highest at 40% (v/v) PEG 400. The release rate of drug from drug-EVA matrix increased withincreased loading dose and temperature. The release rate was proportional to the square root of loading dose. The activationenergy (Ea), which was measured from the slope of log P versus 1000/T, was 5.67 kcal/mol for a 2.0% loaded drug dosefrom the EVA matrix. Among the plasticizer used, diethyl phthalate showed the highest release rate of loxoprofen. Amongthe enhancers used, polyoxyethylene 2-oleyl ether showed the greatest enhancing effect. In conclusion, for the enhancedcontrolled transdermal delivery of loxoprofen, the application of the EVA matrix containing plasticizer and penetrationenhancer could be useful in the development of a controlled drug delivery system.Key words
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
